Health
Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant – The BMJ
The SARS-CoV-2 vaccine produced by the US biotechnology company Novavax is 95.6% effective against the original variant of SARS-CoV-2 but also provides protection…
The SARS-CoV-2 vaccine produced by the US biotechnology company Novavax is 95.6% effective against the original variant of SARS-CoV-2 but also provides protection against the newer variants B.1.1.7 (85.6%) and B.1.351 (60%), preliminary data from clinical trials show.
Interim results have been released from a phase III trial carried out in the UK with more than 15 000 participants aged between 18 and 84, including 27% over the age of 65. The trial tested two doses of the vaccine administered three…
-
General24 hours agoAlleged Croydon Park gunman Artemios Mintzas charged with 25 offences
-
Noosa News10 hours agoSuncorp Stadium upgrades to rival Sydney as seat capacity and infrastructure prioritised
-
General22 hours agoAn open letter to pro-Palestinian protesters
-
Business12 hours agoDroneShield announces new $13 million counter-drone facility as employees top 400